We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.87B
1-Year Est. Return 205.24%
This Fund
S&P 500
This Quarter Est. Return
+48.43%
1 Year Est. Return
+205.24%
3 Year Est. Return
+440.18%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$5.61B
AUM Growth
+$2.03B
Cap. Flow
-$478M
Cap. Flow %
-8.52%
Top 10 Hldgs %
60.15%
Holding
73
New
17
Increased
18
Reduced
15
Closed
18

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$124M
2
VERA icon
Vera Therapeutics
VERA
+$100M
3
GRAL
GRAIL Inc
GRAL
+$88.4M
4
ALKS icon
Alkermes
ALKS
+$59.9M
5
SLNO
Soleno Therapeutics
SLNO
+$54.8M

Top Sells

Rank Stock Value
1
AKRO
Akero Therapeutics
AKRO
+$190M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$159M
3
TERN
Terns Pharmaceuticals
TERN
+$155M
4
ETNB
89bio
ETNB
+$138M
5
GH icon
Guardant Health
GH
+$121M

Sector Composition

Rank Sector Weight
1 Healthcare 78.16%
2 Miscellaneous 21.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BLLN
51
BillionToOne Inc
BLLN
$4.68B
$4.09M 0.07%
+50,000
New +$5.07M
RAPT
52
DELISTED
RAPT Therapeutics
RAPT
$3.74M 0.07%
110,448
-640,974
-85% -$19.9M
IVA
53
Inventiva
IVA
$1.05B
$2.28M 0.04%
+490,000
New +$2.28M
JANX icon
54
Janux Therapeutics
JANX
$1.18B
$1.24M 0.02%
+89,589
New +$2.11M
ANL
55
Adlai Nortye Group ADS
ANL
$947M
$49.5K ﹤0.01%
+34,852
New +$52.8K
ACAD icon
56
Acadia Pharmaceuticals
ACAD
$4.77B
– –
-105,085
Closed -$2.24M
AKRO
57
DELISTED
Akero Therapeutics
AKRO
– –
-4,000,978
Closed -$190M
AUTL
58
Autolus Therapeutics
AUTL
$540M
– –
-2,568,613
Closed -$4.19M
JBIO
59
Jade Biosciences
JBIO
$1.21B
– –
-2,279,892
Closed -$19.7M
AVTX icon
60
Avalo Therapeutics
AVTX
$977M
– –
-144,600
Closed -$1.84M
CDTX
61
DELISTED
Cidara Therapeutics
CDTX
– –
-300,000
Closed -$28.7M
ETNB
62
DELISTED
89bio
ETNB
– –
-9,356,171
Closed -$138M
EXAS
63
DELISTED
Exact Sciences
EXAS
– –
-1,000,000
Closed -$54.7M
GHRS icon
64
GH Research
GHRS
$1.89B
– –
-1,250,000
Closed -$17.9M
GMAB icon
65
Genmab
GMAB
$20.3B
– –
-481,267
Closed -$14.8M
IMA
66
ImageneBio Inc
IMA
$56.9M
– –
-878,516
Closed -$7.16M
OLMA icon
67
Olema Pharmaceuticals
OLMA
$906M
– –
-3,470,172
Closed -$34M
PEPG icon
68
PepGen
PEPG
$218M
– –
-1,200,000
Closed -$5.54M
PTGX icon
69
Protagonist Therapeutics
PTGX
$9.39B
– –
-1,715,691
Closed -$114M
QURE icon
70
uniQure
QURE
$3.19B
– –
-483,092
Closed -$28.2M
XNCR icon
71
Xencor
XNCR
$1.85B
– –
-549,439
Closed -$6.44M
ZURA icon
72
Zura Bio
ZURA
$547M
– –
-259,014
Closed -$1.12M
CLYM
73
Climb Bio
CLYM
$864M
– –
-509,789
Closed -$1.02M
1 2
3

Similar funds

PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
EWM
Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return
NP
NorthRock Partners Minneapolis, Minnesota $6.89B AUM 19.83% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $6.92B AUM 24.7% 1-Year Est. Return
RCWMU
Rothschild & Co Wealth Management (UK) London, United Kingdom $6.93B AUM 1.4% 1-Year Est. Return
CA
Cambridge Associates Boston, Massachusetts $6.93B AUM 17.96% 1-Year Est. Return
LIP
Liontrust Investment Partners London, United Kingdom $6.8B AUM 23.31% 1-Year Est. Return
CI
Cincinnati Insurance Fairfield, Ohio $6.94B AUM 20.24% 1-Year Est. Return

Deep Track Capital's Q4 2025 Portfolio in Review

As of Q4 2025, Deep Track Capital held 73 positions worth $5.61B, up 57% from $3.58B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Deep Track Capital withdrew a net $478M in Q4 2025, closing 18 positions and reducing 15 holdings. Its most notable exit was Akero Therapeutics, an estimated $190M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, Deep Track Capital opened a new position in Vera Therapeutics worth $143M.

  • Deep Track Capital's largest Q4 2025 buy was Vera Therapeutics: 2,821,135 shares worth $143M.
  • Deep Track Capital added most to BioMarin Pharmaceuticals in Q4 2025, an estimated $124M increase.
  • Deep Track Capital's biggest Q4 2025 reduction was Ionis Pharmaceuticals, cutting an estimated $159M.
  • Deep Track Capital fully exited Akero Therapeutics in Q4 2025, selling an estimated $190M.
  • Deep Track Capital's ten largest holdings make up 60% of its $5.61B portfolio in Q4 2025.
  • Deep Track Capital opened 17 new positions and closed 18 in Q4 2025.
  • Deep Track Capital's portfolio value rose 57% quarter-over-quarter to $5.61B.

Based on Deep Track Capital's 13F filing for Q4 2025, filed 13 Feb 2026.